Imatinib may have potential applications in prostate cancer treatment [55], as it can induce resistance by recruiting DNMT3A and EZH2 to the promoter region of PTEN in leukemia patients, thereby downregulating the transcription of this gene [56]. This evidence concerns the gene EZH2 and leukemia.